Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.40 |
| ▸ | DDX3X | O00571 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
| ▸ | RAF1 | P04049 | 4/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059925 | 0.92 | MAPK14 (0.45) | IMPDH2KDRBRAFRAF1MAPK13 | |
| SCHEMBL5055293 | 0.91 | MAPK14 (0.47) | KDRBRAFMAPK13MAPK14 | |
| SCHEMBL5052156 | 0.90 | ABL1 (0.44) | KDRBRAFRAF1MAPK13MAPK14 | |
| SCHEMBL5056558 | 0.90 | IMPDH2 (0.38) | IMPDH2DDX3XKDRBRAFRAF1 | |
| SCHEMBL5055087 | 0.90 | KDR (0.40) | IMPDH2DDX3XKDRBRAFRAF1 | |
| SCHEMBL5056313 | 0.87 | FDPS (0.40) | KDRBRAFMAPK13MAPK14ROCK2 | |
| SCHEMBL5054508 | 0.87 | KDR (0.37) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL5055064 | 0.87 | ABL1 (0.46) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL5056463 | 0.87 | RAF1 (0.51) | KDRBRAFRAF1MAPK13MAPK14 | |
| SCHEMBL5060620 | 0.85 | KDR (0.54) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | IMPDH2 1641/4885DDX3X 3159/4885KDR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.